Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-11-26
2000-06-06
Hauda, Karen M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4353201, 435375, A61K 4800
Patent
active
060718935
ABSTRACT:
A method is disclosed of reducing viral replication of a virus of the paramyxoviridae family in a host, comprising administering to the host an antigen of the virus in combination with an effective adjuvant amount of interleukin-12 (IL-12). Human viruses of the paramyxoviridae family include paramyxoviruses (e.g., parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3 and parainfluenza virus 4), morbilliviruses (e.g., measles virus) and pneumoviruses (e.g., respiratory syncytial virus); other non-human viruses of the paramyxoviridae family include canine distemper virus, bovine respiratory syncytial virus, Newcastle disease virus and rhinderpest virus. A composition is also disclosed comprising a mixture of an antigen of a virus of the Paramyxoviridae family and an effective adjuvant amount of interleukin-12 (IL-12).
REFERENCES:
patent: 5571515 (1996-11-01), Scott et al.
Marshall, E. "Gene Therapy's Growing Pains," Science, vol. 269: 1050-1055, Aug. 25, 1995.
Mulligan, R.C. "The Basic Science of Gene Therapy," Science, vol. 260: 926-931, May 14, 1993.
Verma et al. "Gene Therapy-promises, problems, and prospects," Nature, vol. 389: 239-242, Sep. 18, 1997.
Trinchieri, G., "Interleukin-12 and its role in the generation of T.sub.H 1 cells", Immunology Today, 14(7):335-338 (1993).
Orange, J.S., et al., "Effects of IL-12 on the Response and Susceptibility to Experimental Viral Infections", Journal of Immunology 152:1253-1264 (1994).
Scott, P., "IL-12: Initiation Cytokine for Cell-Mediated Immunity", Science 260:496-497 (Apr. 1993).
Graham, B.S., et al., "Priming Immunization Determines T Helper Cytokine mRNA Expression Patterns in Lungs of Mice Challenged with Respiratory Syncytial Virus", J. Immunol. 151(4):2032-2040 (Aug. 15, 1993).
Tripp, C.S., et al., "Interleukin 12 and tumor necrosis factor .varies. are costimulators of interferon .gamma. production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist", Proc. Natl. Acad. Sci USA 90:3725-3729 (Apr. 1993).
Heinzel, F.P., et al., "Recombinant Interleukin 12 Cures Mice Infected with Leishmania major", The J. of Exp. Med. 177:1505-1509 (May 1993).
Sypek, J.P., et al., "Resolution of Cutaneous Leishmaniasis: Interleukin 12 Initiates a Protective T Helper Type 1 Immune Response," J. Exp. Med. 177-1797-1802 (Jun. 1993).
Alfonso, L.C.C., et al., "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania major", Science 263:235-237 (Jan. 14, 1994).
Gazzinelli, R.T., et al., "Interleukin 12 is required for the T-lymphocyte-independent induction of interferon .gamma. by an intracellular parasite and induces resistance in T-cell-deficient hosts", Proc. Natl. Acad. Sci. USA 90:6115-6119 (Jul. 1993).
Gately, M.K., et al., "Regulation of Human Cytolytic Lymphocyte Responses by Interleukin-12", Cellular Immunology 143:127-142 (1992).
Naume, B., et al., "A Comparative Study of IL-12 (Cytotoxic Lymphocyte Maturation Factor)-, IL-2-, And IL-7-Induced Effects On Immunomagnetically Purified CD56.sup.+ NK Cells", J. Immunology 148(8):2429-2436 (Apr. 15, 1992).
Schoenhaut, D.S., et al., "Cloning and Expression of Murine IL-12", J. of Immunology 148(11):3433-3440 (Jun. 1, 1992).
Morris, S.C., et al., "Effects of IL-12 on in Vivo Cytokine Gene Expression and Ig Isotype Selection", J. of Immunology 152:1047-1056 (1994).
Audibert, F.M., and Lise, L.D., "Adjuvants: current status, clinical perspectives and future prospects", Immunology Today 14(6):281-284 (1993).
Locksley, R.M., "Interleukin 12 in host defense against microbial pathogens", Proc. Natl. Acad. Sci. USA 90:5879-5880 (Jul. 1993).
Hsieh, C-S, et al., "Development of T.sub.H 1 CD4.sup.+ T Cells Through IL-12 Produced by Listeria-Induced Macrophages", Science 260:547-549 (Apr. 23, 1993).
Manetti, R., "Natural Killer Cell Stimulatory Factor (Interleukin 12 [IL-12]) Induces T Helper Type 1 (Th1)-specific Immune Responses and Inhibits the Development of IL-4-producing Th Cells", J. Exp. Med. 177:1199-1204 (Apr. 1993).
Chan, S.H., et al., "Induction of Interferon .gamma. Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers", J. Exp. Med. 173:869-879 (Apr. 1991).
D'Andrea, A., et al., "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells", J. Exp. Med. 176:1387-1398 (1992).
Stern, A.S., et al., "Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells", Proc. Natl. Acad. Sci. USA 87:6808-6812 (Sep. 1990).
Kobayashi, M, et al., "Identification And Purification Of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine With Multiple Biologic Effects On Human Lymphocytes", J. Exp. Med. 170:827-845 (Sep. 1989).
Rabinovich, N.R et al., "Vaccine Technologies: View to the Future", Science, 265(5177):1401-1404 (Sep. 2, 1994).
Tang, Y.-W. and Graham, B.S., "Interleukin-12 Treatment during Immunization Elicits a T Helper Cell Type 1-like Immune Response in Mice Challenged with Respiratory Syncytial Virus and Improves Vaccine Immunogenicity", J. of Infectious Diseases, 172(3):734-738 (1995).
Li, X., "Protection against Respiratory Syncytial Virus Infection by DNA Immunization", J. Exp. Med., 188(4):681-688 (1998).
Graham Barney S.
Tang Yi-Wei
Hauda Karen M.
Vanderbilt University
LandOfFree
Interleukin-12 as an adjuvant for paramyxoviridae vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-12 as an adjuvant for paramyxoviridae vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-12 as an adjuvant for paramyxoviridae vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2213677